Show simple item record

dc.contributor.authorTitova, Nataliya
dc.contributor.authorMartinez-Martin, Pablo 
dc.contributor.authorKatunina, Elena
dc.contributor.authorChaudhuri, K Ray
dc.date.accessioned2022-05-25T11:13:21Z
dc.date.available2022-05-25T11:13:21Z
dc.date.issued2017-12
dc.identifier.citationJ Neural Transm (Vienna). 2017 Dec;124(12):1529-1537.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14527
dc.description.abstractHolistic management of Parkinson's disease, now recognised as a combined motor and nonmotor disorder, remains a key unmet need. Such management needs relatively accurate definition of the various stages of Parkinson's from early untreated to late palliative as each stage calls for personalised therapies. Management also needs to have a robust knowledge of the progression pattern and clinical heterogeneity of the presentation of Parkinson's which may manifest in a motor dominant or nonmotor dominant manner. The "advanced" stages of Parkinson's disease qualify for advanced treatments such as with continuous infusion or stereotactic surgery yet the concept of "advanced Parkinson's disease" (APD) remains controversial in spite of growing knowledge of the natural history of the motor syndrome of PD. Advanced PD is currently largely defined on the basis of consensus opinion and thus with several caveats. Nonmotor aspects of PD may also reflect advancing course of the disorder, so far not reflected in usual scale based assessments which are largely focussed on motor symptoms. In this paper, we discuss the problems with current definitions of "advanced" PD and also propose the term "complex phase" Parkinson's disease as an alternative which takes into account a multimodal symptoms and biomarker based approach in addition to patient preference.es_ES
dc.description.sponsorshipNT is supported by an academic educational grant from Britannia, UCB pharmaceuticals and the Parkinson’s Disease NonMotor Group.es_ES
dc.language.isoenges_ES
dc.publisherSpringer es_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectParkinson’s diseasees_ES
dc.subjectAdvancedes_ES
dc.subjectComplexes_ES
dc.subjectNonmotor symptomses_ES
dc.subjectPersonalised medicinees_ES
dc.subjectNonmotor subtypeses_ES
dc.subject.meshDisease Management es_ES
dc.subject.meshParkinson Disease es_ES
dc.subject.meshDisease Progression es_ES
dc.subject.meshHumans es_ES
dc.subject.meshSeverity of Illness Index es_ES
dc.titleAdvanced Parkinson's or "complex phase" Parkinson's disease? Re-evaluation is neededes_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID29116411es_ES
dc.format.volume124es_ES
dc.format.number12es_ES
dc.format.page1529-1537es_ES
dc.identifier.doi10.1007/s00702-017-1799-3es_ES
dc.contributor.funderBritannia Royal Naval Collegees_ES
dc.contributor.funderUCB Pharmaceuticalses_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1435-1463es_ES
dc.relation.publisherversionhttps://doi.org/10.1007/s00702-017-1799-3es_ES
dc.identifier.journalJournal of Neural Transmission (Vienna, Austria: 1996)es_ES
dc.repisalud.centroISCIII::Centro Nacional de Epidemologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional